Clinical trials for cancer in San Antonio

The Methodist Healthcare Cancer Network is one of the leading cancer research programs in Texas providing advancements in cancer treatments. We bring the latest cancer treatments to San Antonio by participating in cancer care research trials and studies. Clinical trials provide patients with either the best treatment currently available or a new and possibly more effective therapy.

For more information about our cancer clinical trials, please call askSARAH at (210) 507-0941.

How do clinical trials work?

Studies are broken down into different phases, each focusing on certain things.

  • Phase 1 investigates safety, side effects and the best dose of study drugs.
  • Phase 2 determines the effectiveness and safety.
  • Phase 3 looks at effectiveness, side effects and safety compared with other treatments.
  • Phase 4 gathers more information after the Food and Drug Administration (FDA) approves the drug, and it is on the market.

Each cancer trial has a written detailed study design called a protocol. A protocol includes why the trial is needed, the purpose of the trial, what drug or drugs are being tested and who can join the study. It also includes:

  • Safety measures
  • How outcomes will be measured
  • What information will be gathered about you

Standard treatment

Standard treatment is a treatment experts agree is appropriate, accepted and widely used. As with any treatment, it will have side effects. For example, the standard treatment for some blood cancers may only be somewhat effective, in these instances, you may want to consider a clinical trial.


Randomization enables doctors to compare new treatments with standard treatments. Patients are divided into different groups at random. The control group receives the best standard treatment available and the treatment group receives the treatment under study. Sometimes a placebo may be used, but this happens rarely in cancer studies.


A placebo is designed to look like the medicine being tested, but it is not active. A study may compare standard treatment plus a new treatment to standard treatment plus a placebo. You are told if the study uses a placebo, but you will not know if you are getting the placebo, nor will your study team. This is called “blinding,” which allows the research team to look at your side effects without bias.

Types of clinical trials we offer

Your eligibility depends on several criteria, including your age and sex, your cancer type and stage, previous treatments and your overall medical history. If you’re interested in participating in a clinical trial, view the list of open San Antonio trials below and talk to your doctor to determine which one may be right for you.

Current trials at The Sarah Cannon Pediatric Transplant and Cellular Therapy Program at Methodist Children’s Hospital

  • Other

    • PIDTC: Prospective Natural History Studies of Diagnosis, Treatment and Outcomes of Children with SCID Disorders, Chronic Granulomatous Disease, and Wiskott-Aldrich Syndrome
  • Acute Myeloid Leukemia (AML)

    • PBMTC ONC 1701 (EndRAD): A phase II pilot trial to estimate survival after a non-TBI based conditioning regimen in patients diagnosed with B-ccule lymphoblastic leukemia who are pre-allogeneic hematopoietic cell transplantation next generation sequence minimal residual disease negative
  • STAR- HLA Matched Related Hematopoietic Stem Cell Transplantation for Children with Less Severe Sickle Cell Disease: a Sickle Transplant Alliance for Research (STAR) Trial
  • Vanderbilt: BMT 12108: A Non-Myeloablative Conditioning and Transplantation of partially HLA-Mismatched and HLA-Matched Bone Marrow for Patients with Sickle Cell Disease and Other Hemoglobinopathies

Current trials at The Sarah Cannon Transplant and Cellular Therapy Program at Methodist Hospital

Acute Myeloid Leukemia (AML)

  • BMT 41 AbbVie: A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML)
  • BMT 37 Mana:  Phase 1 Study of Escalating Single and Multiple Doses of Mana 312 (Multi Tumor-Associated Antigen T cells) Administered to Adult Subjects with Acute Myeloid Leukemia or Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplant


  • SCRI BMT 36 Orca TRGFT-201:  A multicenter Phase Ib trial for patients with advanced hematologic malignancies undergoing allogeneic hematopoietic cell transplantation with TregGraft, a T cell depleted graft with additional infusion of conventional tT cells and regulatory T cells


  • YM 177 Caliber: A phase 1 open label, dose escalating study evaluating the safety tolerability pharmacokinetics, pharmacodynamics and clinical activity of the combination of CLBR001, an engineered autologous T cell product, and SW1019, an antibody based biologic, in patients with relapsed/refractory B cell malignancies
  • LYM 158 Crispr:  A Phase 1 dose escalation and cohort expansion study of the safety and efficacy of Anti-CD19 Allogeneic CRISP-CAS9-Engineered T Cells (CTX110) in Subjects with relapsed or refractory B cell Malignancies
  • LYM 183 Fate:  A Phase I, Open-label, multicenter study of FT596 as a monotherapy and in combination with Rituximab or Obinutuzumab in subjects with relapsed/refractory B-cell lymphoma and chronic lymphocytic leukemia

Multiple Myeloma

  • SCRI MM 113 Allogene: A Single-Arm, Open-Label, Phase 1 Study of the Safety, Efficacy, and Cellular kinetics/Pharmacodynamics of ALLO-715 and ALLO-647 to Evaluate an Anti-BCMA Allogeneic CAR T Cell Therapy with and without Nirogacestat in Subjects With elapsed/Refractory Multiple Myeloma
  • MM 138: Allogene 605, A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-647 and ALLO-605, an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma
  • HR 70: Fate: A phase 1, open label, multicenter study of FT538 as monotherapy in relapsed/refractory acute myelogenous leukemia and in combination with monoclonal antibodies in relapsed/refractory multiple myeloma
  • SCRI MM 139: Pfizer: A Phase 2 non-randomized, two-cohort study to evaluate the efficacy, safety and pharmacokinetics PF-06863135, A BCMA-CD3 bispecific antibody, in participants with triple-class refractory multiple myeloma


  • ALL 06 Autolus: An open label, multi-centre, phase Ib/II study evaluating the safety and efficacy of Auto1, a CAR T cell treatment targeting CD19, in adult patients with relapsed or refractory B cell Acute Lymphoblastic Leukemia
  • HR 63: Nkarta:  A Phase 1 Study of NKX101, an Activating Chimeric Receptor Natural Killer (ACR NK) Cell Therapy, in subjects with Hematological Malignancies or Dysplasias

About Sarah Cannon Cancer Institute

Methodist Healthcare is part of Sarah Cannon, the Cancer Institute of HCA Healthcare. Our family of hospitals provides comprehensive cancer services with convenient access to cutting-edge therapies for people facing cancer in our communities. From diagnosis, to treatment and survivorship care, our oncology expertise ensures you have access to locally-trusted care with the support of a globally-recognized network.

askSARAH helpline

Have cancer questions? We can help. askSARAH is a dedicated helpline for your cancer-related questions. Our specially trained nurses are available 24/7, and all calls are confidential. Contact askSARAH at (210) 507-0941.